scispace - formally typeset
F

Frederick Klauschen

Researcher at Humboldt University of Berlin

Publications -  238
Citations -  17312

Frederick Klauschen is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 170 publications receiving 12451 citations. Previous affiliations of Frederick Klauschen include Charité & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions.

TL;DR: The role of dendritic cell (DC) subsets in initial activation of the two T cell types and their co-operation is addressed, delineate the complex choreography of cellular interactions underlying effective cell-mediated anti-viral responses, and has implications for basic DC subset biology.
Journal ArticleDOI

Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

TL;DR: A novel contour-based “minimum-model” cell detection and segmentation approach that uses minimal a priori information and detects contours independent of their shape and allows for an accurate segmentation of a broad spectrum of normal and disease-related morphological features without the requirement of prior training.
Journal ArticleDOI

Evaluation of automated brain MR image segmentation and volumetry methods.

TL;DR: Since the discrepancies between results reach the same order of magnitude as volume changes observed in disease, these effects limit the usability of the segmentation methods for following volume changes in individual patients over time and should be taken into account during the planning and analysis of brain volume studies.
Journal ArticleDOI

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

TL;DR: This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer and opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice.